Figure 3.

IDB0076 retains the binding affinity for VEGFA and NRP1 simultaneously in the pharmacokinetic (PK) assay. (a) Sprague–Dawley (SD) rats received a single i.v. injection of 10 mg/kg IDB0076 or bevacizumab via the tail vein. The serum concentrations of IDB0076 and bevacizumab are presented, as determined based on their binding activity for immobilized human VEGFA in an enzyme-linked immunosorbent assay. (b) The serum concentration of IDB0076 was measured based on its binding activity for immobilized VEGFA and was determined by means of the biotinylated NRP1 b1b2 domain. Each symbol and error bar represent the arithmetic mean and the standard deviation of each drug at a given time point (n = 5).